Press releases
-
-
-
-
Internal link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2
-
Internal link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
-
Internal link ProQR to Present at Cowen Health Care Conference
-
-
-
-
Internal link ProQR to Host R&D Day in New York on January 29
-
-
Internal link ProQR Announces Results for the Third Quarter of 2016
-
-
-
-
Internal link ProQR Announces Results for the Second Quarter of 2016
-
-
Internal link ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC
-
Internal link ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation
-
Internal link ProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference
-
Internal link ProQR Announces Results for the First Quarter of 2016
-
-
Internal link ProQR Announces Annual Meeting of Shareholders
-
-